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Abstract
Background: Eradication of hepatitis C virus (HCV) using direct-acting agents (DAA) has been associated with a
financial burden to health authorities worldwide. We aimed to evaluate the guideline-based treatment costs by
DAAs from the perspective of the Brazilian Ministry of Health (BMoH).
Methods: The activity based costing method was used to estimate the cost for monitoring/treatment of genotype-1
(GT1) HCV patients by the following strategies: peg-interferon (PEG-IFN)/ribavirin (RBV) for 48 weeks, PEG-IFN/RBV plus
boceprevir (BOC) or telaprevir (TEL) for 48 weeks, and sofosbuvir (SOF) plus daclastavir (DCV) or simeprevir (SIM) for
12 weeks. Costs were reported in United States Dollars without (US$) and with adjustment for purchasing power parity
(PPP$). Drug costs were collected at the National Database of Health Prices and an overview of the literature
was performed to assess effectiveness of SOF/DCV and SOF/SIM regimens in real-world cohorts.
Results: Treatment costs of GT1-HCV patients were PPP$ 43,176.28 (US$ 24,020.16) for PEG-IFN/RBV, PPP$
71,196.03 (US$ 39,578.23) for PEG-IFN/RBV/BOC and PPP$ 86,250.33 (US$ 47,946.92) for PEG-IFN/RBV/TEL.
Treatment by all-oral interferon-free regimens were the less expensive approach: PPP$ 19,761.72 (US$ 10,985.
90) for SOF/DCV and PPP$ 21,590.91 (US$ 12,002.75) for SOF/SIM. The overview reported HCV eradication in
up to 98% for SOF/DCV and 96% for SOF/SIM.
Conclusion: Strategies with all oral interferon-free might lead to lower costs for management of GT1-HCV
patients compared to IFN-based regimens in Brazil. This occurred mainly because of high discounts over international
DAA prices due to negotiation between BMoH and pharmaceutical industries.
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Background
Chronic hepatitis C (CHC) remains a major public health
issue that might lead to cirrhosis and its complications,
such as portal hypertension and hepatocellular carcinoma
[1]. Eradication of hepatitis C virus (HCV) has been asso-
ciated with lower rates of liver-related complications
[2]. Transient elastography (TE) by FibroScan® (Echo-
Sens, Paris, France) is a validated method to liver fi-
brosis assessment [3] and seems to be cost-effective
to diagnose cirrhosis compared to liver biopsy [4].
The high efficacy of direct-acting antiviral drugs
(DAAs) has revolutionized the management of pa-
tients with CHC. High rates of sustained virological
response (SVR), defined as undetectable serum HCV-
RNA levels 12 weeks after completing treatment, has
been obtained by DAA treatment in patients with ad-
vanced liver fibrosis or compensate cirrhosis [5].
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However, the decrease of the burden of liver disease
in CHC by DAA treatment might be associated with
high costs to health authorities worldwide [6]. Public
health strategies should be implemented to promote
primary care access to interferon-free regimes, espe-
cially in low to middle-income countries with high
prevalence of CHC.
Drug prices are very important in HCV management
but they are clearly not the only costs to be considered
in the analysis [7]. The decision to incorporate new
drugs in guidelines for CHC management should take
into account the cost and cost-effectiveness analysis.
The evidence base from economic evaluations of new
healthcare technologies has been limited by the quality
of the available data, strengths and weaknesses of differ-
ent methods used for cost determination and differences
among public health systems worldwide [8]. In Brazil, it
is estimated that 1.4 to 1.7 million of people are living
with CHC [9], most of them genotype-1 (GT1) HCV
[10] and up to 20% with advanced fibrosis or cirrhosis
[11]. Recently, the Brazilian Ministry of Health (BMoH)
has recommended the use of DAAs for CHC treatment
due to high discounts given by pharmaceutical compan-
ies. Since July 2015, patients with advanced fibrosis
(METAVIR F ≥ 3) have free access to these drugs [12].
However, few studies have investigated the cost for CHC
treatment with DAAs in a low to middle-income coun-
try. The aim of this study was to evaluate the guideline-
based treatment costs by DAAs from the perspective of
a public national reference healthcare institute in Brazil.
In addition, we reviewed the literature for effectiveness
of all-oral interferon-free regimens available in Brazil in
real-life cohort studies.
Methods
Study design and setting
This cost-analysis study used cost data collected in a ter-
tiary center for treatment of infectious diseases: National
Institute of Infectious Diseases Evandro Chagas-Oswaldo
Cruz Foundation (INI/FIOCRUZ) at Rio de Janeiro, Brazil.
INI/FIOCRUZ has been playing an important role for the
BMoH in development of public health policies and strat-
egies for prevention and treatment of infectious diseases,
including viral hepatitis. In the Brazilian Public Health
System, known as Sistema Único de Saúde (SUS), individ-
uals can have free access to HCV treatment whether con-
firmed presence of liver fibrosis. According to the
recommendations for HCV treatment from the BMoH,
treatment was delivery for free in patients with liver fibro-
sis stages F ≥ 2 until 2012. However, from 2013 to now-
adays, the threshold for free-treatment access has changed
for fibrosis stages F ≥ 3. This analysis simulated follow-up
and antiviral regimens exclusively for treatment of GT1-
HCV patients according to the recommendation of BMoH
from 2011 to 2015.
Method for cost determination
The activity based costing (ABC) method was used for
cost determination. This micro-costing method identifies
different activities that the institution performs and
includes the corresponding indirect costs (e.g. manage-
ment costs) to estimate total cost of a procedure. ABC
method recognizes the relationship between costs, activ-
ities (called cost drivers) and products (exams or medical
visit) taking into account this relationship in the costing
analysis [13]. Secondary data were obtained from: (i)
public access production resources from the Department
of Statistics; (ii) inventory of permanent material; (iii) re-
cords of expenditures with resources from the Financial
Department for a one-year (2013) period (to correct the
potential seasonal expenses due to diseases outbreaks in
infectious diseases); and (iv) cost of 450 diagnostic tests
and 100 sub-types of clinical procedures. Administrative
costs were estimated through the determination of the
proportional contribution of each activity to the pooled
expenses and considered for all diagnostic tests and clin-
ical procedures. Prices in national currency [Brazilian
Real (BRL)] and inflated to average prices of July of 2015
in United States Dollars according to the World Bank,
without (exchange rate = 3.11) and with adjustment for
purchasing power parity (PPP adjustment rate = 1.73).
We report these as the “nominal price” (US$) and the
“PPP-adjusted price” (PPP$), respectively.
Costs of personnel, blood analysis tests and medical visits
Personnel costs for each procedure were calculated
based on the annual salary payment of each employee
and the working time spent in the specific activity. At
INI/FIOCRUZ, salaries are determined according to
employee’s specialization (i.e., people with PhD degree
have higher salaries compared to those without) for
individuals working in similar activities. Regarding ex-
penditures with blood analysis tests, we considered
costs of materials needed to perform the test, such as
kits and reagents. Methodology for cost determination
of non-invasive methods for liver fibrosis assessment
were detailed in the Supplementary Material. Briefly,
the following aspects were taken into account to esti-
mate the cost per unit of TE (i) the price and depre-
ciation of the FibroScan® machine; (ii) annual
maintenance by M probe calibration; (iii) salaries of
personnel who perform the examination and (iv) in-
direct administrative costs. We reported the price of
TE adjusted with the opportunity cost of using public
resources for implementation of new technologies
(cost of capital). Costs with specific material for liver
biopsy [Menghini needle 16G (Biomedical, Florence,
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Italy)] and histological analysis, as well as personnel
costs and cost for a day-clinic hospitalization were
considered for estimation of total cost to perform a
liver biopsy. The market prices were considered for
diagnostic tests not performed at INI/FIOCRUZ.
Cost of antiviral drugs for CHC treatment
Drug costs were collected in a web-based public domain site
that describes the prices paid by the BMoH for all drugs in-
corporated in the Public Health System and purchased from
the pharmaceutical industry (Database of Health Prices –
“Banco de Preços em Saúde” - accessible at: http://www.sau-
de.gov.br/bps). A weighted-mean price for each antiviral
drug was estimated taking into account all drug payments
made by the BMoH from January to December 2015. We
then calculated the price for a single-dose of PEG-interferon
α-2a 180 mcg (PEG-IFN) [Pegasys® - Roche] and a single
capsule or tablet for ribavirin (RBV) [generic by BMoH],
boceprevir (BOC) [Victrelis® – Merk], telaprevir (TEL)
[Incivek® - Vertex Pharmaceuticals], sofosbuvir (SOF)
[Sovaldi® – Gilead], daclastavir (DCV) [Daklinza® -
Bristol-Myers Squibb] and simeprevir (SIM) Olysio® –
Janssen Pharmaceuticals].
Strategies for treatment of GT1-HCV patients according to
the BMoH guidelines
In the present study, we compared the strategies for
HCV treatment of GT1 patients as recommended by the
BMoH from 2011 to 2015. During this period, Brazilian
guidelines for CHC treatment were published in 2011,
2013 and 2015. In 2011, GT1 patients should be treated
by PEG-IFN plus RBV for 48 weeks and a liver biopsy
with significant fibrosis (METAVIR F ≥ 2) was necessary
for treatment access (regimen BMoH-2011) [14]. In
2013, presence of advanced fibrosis (liver biopsy META-
VIR F ≥ 3 or TE ≥ 9.6 kPa) allowed the addition of first
generation protease inhibitors [BOC for 44 weeks (regi-
men BMoH-2013A) or TEL for 12 weeks (regimen
BMoH-2013B)] to PEG-IFN/RBV during 48 weeks [15].
More recently, in 2015, all-oral and interferon-free
regimens [SOF plus DCV for 12 weeks (regimen
BMoH-2015A) or SOF plus SIM for 12 weeks (regi-
men BMoH-2015B)] were recommended for GT1
HCV patients. Patients with decompensated cirrhosis,
HIV co-infection or previous failure with PEG-IFN/
RBV ± BOC or TEL might be treated by SOF/DCV
24 weeks. In addition, serological biomarkers or TE
could replace liver biopsy for free-access to DAA
treatment [12]. In all scenarios, liver fibrosis was
staged for treatment access and patients were
followed with blood tests and medical visits. Table 1
summarizes the strategies for treatment of GT1 HCV
patients according to the BMoH guidelines from 2011
to 2015.
Literature review for efficacy of SOF/DCV and SOF/SIM
regimens in real-life scenario
We systematically searched the references using the fol-
lowing predetermined inclusion criteria: cohort study that
included GT1 HCV patients treated in real-life scenario
by SOF/DCV or SOF/SIM ± RBV for 12 weeks. This
search was performed in June 2017 at MEDLINE
(PubMed) (1966–2017) using the following terms: [“sofos-
buvir” OR “Sovaldi®” OR “GS-7977” OR “simeprevir” OR
“Olysio®” OR“TMC-435” OR “daclastavir” OR “Daklinza®”
OR “BMS-790052”] AND [“hepatitis C”] AND [“real-
world” OR “real-life”] (Additional file 1: Table S1).
Results
Costs for liver fibrosis assessment
The estimated costs of TE with personnel, machine and
administrative costs were PPP$ 40.08, 29.80 and 24.78,
respectively. The nominal and PPP-adjusted costs of a
single TE exam were PPP$ 95.32 (US$ 53.32). The ad-
justment using the opportunity cost lead to an increase
in up 50% of TE price (Additional file 1: Table S2). Costs
of APRI and FIB-4 were estimated at PPP$ 27.85 (US$
15.48) and PPP$ 36.58 (US$ 20.33), respectively. Total
cost for liver biopsy was PPP$ 834.41 (US$ 482.32)
including material to perform liver biopsy and histo-
logical analysis [PPP$ 80.75 (US$ 46.68)], personnel
costs [PPP$ 301.47 (US$ 174.26)] and cost for day-clinic
hospitalization [PPP$ 452.19 (US$ 261.38)].
Costs for GT1 HCV treatment
The estimated price of GT1 HCV treatment drugs was
an important source of variability in the total cost for
HCV treatment. PEG-IFN α-2a 180 mcg cost PPP$
648.00 (US$ 360.22) per weekly injection and RBV was
the least expensive drug costing PPP$ 106.05 (US$
58.80) per week. The regimen PEG-IFN (180 mcg SC
weekly)/RBV (1250 mg PO daily if body weight ≥ 75 kg)
cost PPP$ 754.05 or US$ 419.18 per week. Considering
the first generation protease inhibitors (PI), TEL had a
higher cost compared to BOC [PPP$ 87.01 (US$ 48.37)
vs PPP$ 7.96 (US$ 4.42) per tablet). The weekly costs for
treatment by BOC (800 mg PO q8hr) and TEL (750 mg
PO q8hr) were PPP$ 668.64 and 3654.42, respectively.
Thus, the weekly costs for PEG-IFN/first generation PI
regimens ranges from PPP$ 1422.69 (with BOC) and
4408.47 (with TEL). Considering the DAAs, the NS5A
inhibitor DCV 60 mg and the second generation PI SIM
150 mg cost PPP$ 388.78 (US$ 206.09) and PPP$ 541.24
(US$ 300.86) per week, respectively. In addition, SOF
400 mg, a NS5B polymerase inhibitor, had a PPP-
adjusted and a nominal cost of PPP$ 1014.23 and US$
563.78 weekly, respectively. The regimens SOF (400 mg
PO daily)/DCV (60 mg PO daily) and SOF (400 mg PO
daily)/SIM (150 mg PO daily) cost PPP$ 1403.01 and
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US$ 1555.47 per week, respectively. Table 2 summarizes
the nominal and PPP-adjusted costs per unit for tests,
medical care and drugs used in GT1 HCV patient
management.
According to the procedures recommended at the
BMoH’s guidelines, treatment with PEG-IFN/RBV/first
generation PI [BMoH-2013A and B] was the most ex-
pensive approach. In those recommendations, patients
were treated for 48 weeks by PEG-IFN/RBV and BOC
for 44 weeks [total of PPP$ 71,196.03 (US$ 39,578.23)
per patient] or TEL for 12 weeks [total of PPP$
86,250.33 (US$ 47,946.92) per patient]. Treatments by
new all-oral interferon-free regimens were the least
expensive approach: the costs for SOF/DCV [BMoH-
2015A] and SOF/SIM [BMoH-2015B] were PPP$
19,761.72 (US$ 10,985.90) and PPP$ 21,590.91 (US$
12,002.75), respectively (Table 3). In the presence of
decompensated cirrhosis (Child-Pugh B/C), the necessity
to treat with SOF/DCV for 24 weeks leads to an 84% in-
crease in total costs [PPP$ 36,597.71 (US$ 20,345.04)].
In all scenarios, the drug costs were responsible by
approximatively 90% of total cost for treat patients with
CHC. The cost with medical visits and blood analysis
tests fell by up to 40% in treatment with DAAs [guide-
lines BoMH-2015A/B] compared to regimens that used
PEG-IFN [guidelines BMoH 2011 and 2013A/B].
Literature overview for efficacy of SOF/DCV and SOF/SIM
regimens
Out of 150 identified articles, 25 references were eligible
and 14 real-life cohort studies that reported the efficacy
of SOF/DCV (n = 2) or SOF/SIM ± RBV (n = 12) in GT1
Table 1 Description of strategies for treatment of genotype 1 chronic hepatitis C according to the Brazilian Ministry of Health from
2011 to 2015
Guideline Fibrosis
staging
Prerequisite
for treatment
Drugs Duration
(weeks)
Doses Interventions
BMoH-
2011
Liver
biopsy
METAVIR
F≥ 2
PEG-IFN α-2a 180 mcg
[Pegasys® - Roche]
48 1
injection
weekly
PEG-RBV for 48 weeks. Medical visit at screening, baseline, W2, W4
and every 4 weeks for W4 to W48. Response-guided therapy or
stopping rules based on HCV-RNA at W4, W12 and W24. SVR
at W72
RBV 250 mg
[BMoH generic]
48 5
capsules
daily
BMoH-
2013A
TE LSM≥
9.6 kPa
PEG-IFN α-2a 180 mcg
[Pegasys® - Roche]
48 1
injection
weekly
Leading-phase with PEG-RBV for 4 weeks and PEG-RBV/BOC for
44 weeks. Medical visit at screening, baseline, W2, W4, W5, W6
and W8, and every 4 weeks from W8 to W48. Response-guided
therapy or stopping rules based on HCV-RNA on W4, W12 and
W24. SVR at W72RBV 250 mg
[BMoHgeneric]
48 5
capsules
daily
BOC 200 mg
[Victrelis® – Merk]
44 12
tablets
daily
BMoH-
2013B
TE LSM≥
9.6 kPa
PEG-IFN α-2a 180 mcg
[Pegasys® - Roche]
48 1
injection
weekly
PEG-RBV/TEL for 12 weeks and PEG-RBV for 36 weeks. Medical
visit at at screening, baseline, W1, W2 and W4, then every 4
weeks from W4 to W48. Response-guided therapy or stopping
rules based on HCV-RNA on W4, W12 and W24. SVR at W72
RBV 250 mg
[BMoH generic]
48 5
capsules
daily
TEL 375 mg
[Incivek ® - Vertex]
12 6
tablets
daily
BMoH-
2015A
TE or
APRI or
FIB-4
LSM≥ 9.6
kPa or APRI
≥1.5 or
FIB-4≥ 3.25
SOF 400 mg
[Sovaldi® – Gilead]
12 1
tablet
daily
SOF/DCV for 12 weeks. Medical visits at screening, baseline, W2,
W4, W8 and W12. No response-guided therapy or stopping rules.
SVR at W24
DCV 60 mg
[Daklinza® - BMS]
12 1
tablet
daily
BMoH-
2015B
TE or
APRI or
FIB-4
LSM≥ 9.6 kPa
or APRI ≥1.5
or
FIB-4≥ 3.25
SOF 400 mg
[Sovaldi® – Gilead]
12 1
tablet
daily
SOF/SIM for 12 weeks or 24 weeks in presence of decompensated
cirrhosis (Child-Pugh B/C). Medical visits at screening, baseline,
W2, W4, W8 and W12. No response-guided therapy or stopping
rules. SVR at W24
SIM 150 mg
[Olysio – Janssen®]
12 1 tablet
daily
APRI aspartate-to-platelet index, BMoH Brazilian Ministry of Health, BOC boceprevir, DCV daclastavir, FIB-4 fibrosis-4 score, kPa kilopascal, LSM liver stiffness
measurement, PEG-IFN peginterferon, RBV ribavirin, SIM simeprevir, SOF sofosbuvir, SVR sustained-virologic response, TE transient elastography, TEL telaprevir
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HCV patients were included (Fig. 1). Overall, SVR rates for
SOF/DCV± RBV and SOF/SIM±RBV during 12 weeks
ranged from 83 to 98% [16, 17] and from 75 to 96% [18–
29], respectively. SVR rates were lower in presence of cir-
rhosis compared to non-cirrhotic patients (87% vs 98%
with SOF/DCV [17] and 81% vs 91% with SOF/SIM [26].
Higher SVR rates can be achieved in cirrhotic patients
when extending SOF/DCV for 24 weeks [17] or adding
RBV to SIM/SOF [24]. Pol et al. reported lower SVR rates
in GT1a patients compared to GT1b (89% vs 95% with
SOF/DCV 12 weeks) that might be not significant when
extending treatment for 24 weeks (95% for both) [17].
Similar results were observed in patients treated by SOF/
SIM 12 weeks (83% for GT1a vs 90% for GT1b) [26].
Table 4 summarizes SVR rates from real-life cohort studies
that analysed the efficacy of SOF/DCV and SOF/SIM regi-
mens in GT1 patients stratified by GT1 subtype and pres-
ence or absence of cirrhosis or previous treatment.
Table 2 Cost per unit and number of procedures for monitoring and injections/tablets for treatment of genotype 1 chronic hepatitis C
according to different regimens recommended by the BMoH from 2011 to 2015
Cost per unit PEG-RBV PEG-RBV/BOC PEG-RBV/TEL SOF/DCV SOF/SIM
US$ PPP$ n n n n n
Transient elastography 53.35 95.32 – 1 1 1 1
Liver biopsy 482.32 834.41 1 – – – –
Blood analysis tests
WBC. RBC and platelet 10.62 19.11 15 17 16 6 6
Fasting glucose 4.86 8.75 6 6 6 6 6
BUN/creatinine 4.84 8.70 15 16 15 6 6
ALT 4.85 8.73 15 16 15 6 6
AST 4.86 8.74 15 16 15 6 6
Alkaline phosphatases 4.77 8.58 6 6 6 6 6
GGT 4.83 8.69 6 6 6 6 6
Total bilirubin 4.84 8.71 6 6 6 6 6
Albumin 5.07 9.12 6 6 6 6 6
INR 6.68 12.02 6 13 14 6 6
HCV genotype 156.33 281.22 1 1 1 1 1
HCV-RNA 87.05 156.60 8 7 7 2 2
TSH 26.26 47.23 6 6 6 – –
Beta-hCG 45.52 81.88 4 4 4 4 4
Medical follow-up
GP’s medical visit 54.54 98.11 1 1 1 1 1
Specialist’s medical visit 62.92 113.19 14 14 14 5 5
Blood sample collection 37.83 68.06 15 15 15 6 6
Nursing consultation 31.83 57.26 5 5 5 4 4
Drugs
PEG-IFN α-2a 180 mcg – SC injection 360.22 648.00 48 48 48 – –
Ribavirin 250 mg – PO capsule 1.68 3.03 1680 1680 1680 – –
Boceprevir 200 mg – PO tablet 4.42 7.96 – 3612 – – –
Telaprevir 375 mg – PO tablet 48.37 87.01 – – 504 – –
Sofosbuvir 400 mg – PO tablet 80.54 144.89 – – – 84 84
Daclastavir 60 mg – PO tablet 30.87 55.54 – – – 84 –
Simeprevir 150 mg - PO tablet 42.98 77.32 – – – – 84
Costs in United States Dollars (US$) and with purchasing power parity (PPP$) on July 2015. Drug costs estimated as the weighted-mean
price (http://www.saude.gov.br/bps)
BOC boceprevir, DCV daclastavir, PEG-IFN peginterferon, RBV ribavirin, SIM simeprevir, SOF sofosbuvir, TEL telaprevir, WBC white blood cell, RBC red blood cell, BUN
blood urea nitrogen, ALT alanine aminotransferase, AST aspartate aminotransferase, AP alkaline phosphatases, GGT gamma-glutamyl transpeptidase, INR international
normalized ratio, TSH thyroid-stimulating hormone, hCG human chorionic gonadotropin, GP general practicioner
Treatment regimens according to BMoH guidelines: PEG-RBV 48w [BMoH-2011]; PEG-RBV (48w)/BOC 44w [BMoH-2013A]; PEG-RBV (48w)/TEL (12w) [BMoH-2013B];
SOF/DCV 12w [BMoH-2015A] and SOF/SIM 12w [BMoH-2015B]
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Table 3 Monitoring and drugs costs (US$ and PPP-adjusted US$) for treatment of genotype-1 patient with chronic hepatitis C
according to different regimens recommended by the BMoH from 2011 to 2015
PEG-RBV PEG-RBV/BOC PEG-RBV/TEL SOF/DCV SOF/SIM
US$ PPP$ US$ PPP$ US$ PPP$ US$ PPP$ US$ PPP$
TE – – 53.35 95.32 53.35 95.32 53.35 95.32 53.35 95.32
Liver biopsy 482.32 834.41 – – – – – – – –
Total 482.32 834.41 53.35 95.32 53.35 95.32 53.35 95.32 53.35 95.32
Blood analysis tests
WBC. RBC and platelet 159.39 286.72 180.64 324.95 170.02 305.84 63.76 114.69 63.76 114.69
Fasting glucose 29.20 52.52 29.20 52.52 29.20 52.52 29.20 52.52 29.20 52.52
BUN/creatinine 72.58 130.56 77.41 139.26 72.58 130.56 29.03 52.22 29.03 52.22
ALT 72.78 130.92 77.63 139.65 72.78 130.92 29.11 52.37 29.11 52.37
AST 72.91 131.16 77.78 139.91 72.91 131.16 29.17 52.47 29.17 52.47
AP 28.61 51.46 28.61 51.46 28.61 51.46 28.61 51.46 28.61 51.46
GGT 28.99 52.15 28.99 52.15 28.99 52.15 28.99 52.15 28.99 52.15
Total bilirubin 29.04 52.24 29.04 52.24 29.04 52.24 29.04 52.24 29.04 52.24
Albumin 30.44 54.75 30.44 54.75 30.44 54.75 30.44 54.75 30.44 54.75
INR 40.10 72.14 86.89 156.30 93.57 168.32 40.10 72.14 40.10 72.14
HCV genotype 156.33 281.22 156.33 281.22 156.33 281.22 156.33 281.22 156.33 281.22
HCV-RNA 696.43 1252.80 609.38 1096.20 609.38 1096.20 174.11 313.20 174.11 313.20
TSH 157.55 283.41 157.55 283.41 157.55 283.41 – –
Beta-hCG 182.07 327.53 182.07 327.53 182.07 327.53 182.07 327.53 182.07 327.53
Total 1756.41 3159.58 1751.94 3151.54 1733.45 3118.27 849.94 1528.95 849.94 1528.95
Medical follow-up
GP’s medical visit 54.54 98.11 54.54 98.11 54.54 98.11 54.54 98.11 54.54 98.11
Specialist’s visit 880.95 1584.73 880.95 1584.73 880.95 1584.73 314.62 565.97 314.62 565.97
Blood sample 567.52 1020.90 567.52 1020.90 567.52 1020.90 227.01 408.36 227.01 408.36
Nursing consultation 159.15 286.29 159.15 286.29 159.15 286.29 127.32 229.03 127.32 229.03
Total 1662.15 2990.02 1662.15 2990.02 1662.15 2990.02 723.49 1301.47 723.49 1301.47
Drugs
PEG-IFN 180 mcg 17,290.59 31,103.78 17,290.59 31,103.78 17,290.59 31,103.78 – – – –
Ribavirin 250 mg 2828.69 5088.49 2828.69 5088.49 2828.69 5088.49 – – – –
Boceprevir 200 mg – – 15,991.51 28,766.88 – – – – – –
Telaprevir 375 mg – – – – 24,378.69 43,854.45 – – – –
Sofosbuvir 400 mg – – – – – – 6765.68 12,170.68 6765.68 12,170.68
Daclastavir 60 mg – – – – – – 2593.44 4665.30 – –
Simeprevir 150 mg – – – – – – – – 3610.29 6494.49
Total 20,119.28 36,192.27 36,110.79 64,959.15 44,497.97 80,046.72 9359.12 16,835.98 10,375.97 18,665.17
TOTAL COST 24,020.16 43,176.28 39,578.23 71,196.03 47,946.92 86,250.33 10,985.90 19,761.72 12,002.75 21,590.91
Costs in United States Dollars (US$) and with purchasing power parity (PPP$) on July 2015. Drug costs estimated as the weighted-mean
price (http://www.saude.gov.br/bps)
PEG-IFN peginterferon, WBC white blood cell, RBC red blood cell, BUN blood urea nitrogen, ALT alanine aminotransferase, AST aspartate aminotransferase, AP
alkaline phosphatases, GGT gamma-glutamyl transpeptidase, INR international normalized ratio, TSH thyroid-stimulating hormone, hCG human chorionic
gonadotropin, GP general practicioner
Treatment regimens according to BMoH guidelines: PEG-RBV 48w [BMoH-2011]; PEG-RBV (48w)/BOC 44w [BMoH-2013A]; PEG-RBV (48w)/TEL (12w) [BMoH-2013B];
SOF/DCV 12w [BMoH-2015A] and SOF/SIM 12w [BMoH-2015B]
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Discussion
The present study highlighted that GT1 HCV treatment
by effective DAAs might be less expensive than
interferon-based regimens in a low-to-middle income
country, mainly due to price negotiation between health
authorities and pharmaceutical companies and lower
costs with monitoring in the all-oral interferon-free
treatments.
The cost of TE was increased due to the very high
interest rates used in Brazil [30, 31] and higher expenses
with personnel at INI/FIOCRUZ. TE could be less costly
in countries with lower opportunity cost of public funds
and in those where nurses perform the exams. Liver fi-
brosis staging by TE seems to be cost-effective compared
to liver biopsy and it was priced from US$ 21 to US$ 73
in the United Kingdom and up to US$ 145 in the United
States [4].
HCV eradication has been associated with a financial
burden, especially due to high DAAs costs which are
extremely variable worldwide [6]. An analysis of for a
12-week SOF course price (PPP-adjusted) in 30
countries described that Poland (PPP$ 101,063.00),
Turkey (PPP$ 91,339) and United States (PPP$ 64,680)
were the top three ranking countries with the most ex-
pensive prices. On the other hand, India (PPP$ 1861),
Mongolia (PPP$ 2604) and Egypt (PPP$ 3117) were the
countries with the least expensive price for SOF-therapy
[32]. In 36 clinical sites in USA, real-world costs for
PEG-IFN/RBV/BOC 48 weeks, PEG-IFN/TEL 48 weeks
and SOF/SIM 12 weeks were US$ 57,960; US$ 113,400;
US$ 180,600; respectively. In addition, the mean cost per
SVR in all-oral interferon-free was higher in patients
with advanced fibrosis (US$ 167,467 for F3F4 vs 116,579
for F0F1F2) [33]. However, both studies only included
cost of HCV medications, not adjunctive medications,
hospital costs, or projected medical costs. Data from
Europe and Canada reported a total cost [mean
(95%CI)] of €14,559 (13,323–15,836) per patient and
€38,514 (35,244–41,892) per SVR for IFN-based regi-
mens considering treatment, monitoring and complica-
tions [34]. The price disparities among countries might
be explained partly by the pharmaceutical price-setting
Fig. 1 Flow-chart of study selection for the literature overview
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policies used in different countries and negotiation
between health authorities and pharmaceutical compan-
ies. Some countries set prices according to explicit cost-
effectiveness thresholds based on gross domestic prod-
uct (GDP) per capita resulting in high prices without
consideration of budget impact [35]. Therefore, DAA
treatment costs are lower in Brazil compared to others
countries mainly due to intense negotiation of BMoH
with pharmaceutical companies resulting in more than
90% discount over international prices for SOF, DCV
and SIM [9].
In the present study, the reduced price for DAAs and
shorten treatment duration might explain the lower
total cost for HCV eradication with all-oral interferon-
free compared to IFN-based regimens. Weekly prices
for PEG-IFN (US$ 360 or PPP$ 648), BOC (US$ 371 or
PPP$ 672) and TEL (US$ 2030 or PPP$ 3654) were
relatively high and longer duration treatment with IFN-
regimens led to higher costs with monitoring and med-
ical visits (mean cost of PPP$ 6133.15 for IFN-based vs
PPP$ 2830.42 for interferon-free regimens). In addition,
adverse events are more frequent in IFN-based regi-
mens than DAA treatment leading to higher costs. Pre-
vious studies reported that extra medical visits and
drugs used for adverse events treatment, such as
epoetin-α or filgrastim, lead to an increase in costs for
treatment with IFN-based regimens with first gener-
ation PI (BOC/TEL) [36]. Costs per SVR might have 2-
fold increase for patients with thrombocytopenia com-
pared to those with normal platelet count when treated
by IFN-based regimens [€50,907 (95% CI, 44,151–
59,612) vs €26,105 (23,068–29,296)] [34].
Data from real-world cohort studies have been show-
ing higher SVR rates by 12-week course of SOF/DCV
(up to 92%) [17] and SOF/SIM regimens (up to 85%)
[26] compared to IFN-based regimens (up to 40% in cir-
rhotic patients treated by PEG-IFN/RBV/BOC or TEL)
[37]. However, presence of cirrhosis and GT subtype 1a
might lead to lower SVR rates (Table 4). The extension
of SOF/DCV for 24 weeks might be used to achieve
higher SVR rates in cirrhotic patients [17]. In GT1 HCV
infected patients, treatment using DAAs has been con-
sidered as cost-effective [38] and further analysis are
needed to evaluate whether this approach is cost-saving
[39]. In addition, treatment by SOF/DCV or SOF/SIM
result in less medical visits and blood analysis tests for
monitoring, lower rates of adverse events, no need of
subcutaneous injection and lower intake of tablets/day
compared to IFN-regimens. However, presence of
decompensated cirrhosis highly increase the cost of
treatment [from PPP$ 19,761.72to 36, 597.71 (from US$
10,985.9 to 20,345.04] due to extension of SOF/DCV
regimen for 24 weeks. Despite, the lack of cost-
effectiveness studies in Brazil, given the fact that DAA-
regimens are more effective compared to IFN-regimens
and total cost for HCV treatment with all-oral
Table 4 Real-life cohort studies that evaluated efficacy (SVR12) of Sofosbuvir/Daclastavir (SOF/DCV) or Sofosbuvir/Simeprevir (SOF/
SIM) regimens for treatment of HCV mono-infected genotype-1 patients
Authors Year Local Regimen Overall Non-cirrhosis Cirrhosis Naive Experimented GT 1a GT 1b
n SVR n SVR n SVR n SVR n SVR n SVR n SVR
Sofosbuvir (400 mg)/Daclastavir (60 mg) regimen studies
Pol et al. [17] 2017 France SOF/DCV 12w 160 92% 66 98% 94 87% 64 88% 96 95% 73 95% 83 89%
SOF/DCV 24w 439 95% 97 97% 342 94% 48 85% 391 96% 210 95% 209 95%
Welzel et al. [16] 2016 Europe SOF/DCV ± RBV 12w 319 98% – – – – – – – – 151 99% 155 97%
Sofosbuvir (400 mg)/Simeprevir (150 mg) regimen studies
Marino et al. [[28] 2017 Spain SOF/SIM ± RBV 12w 835 92% – – 835 92% – – – – – – – –
Ramos et al. [29] 2017 Spain SOF/SIM 12w 179 93% – – – – – – – – – – – –
Chang et al. [27] 2017 USA SOF/SIM 12w 21 91% – – – – – – – – – – – –
Sulkowski et al. [26] 2016 USA SOF/SIM 12w 639 85% 272 91% 367 81% 65 – – – 371 83% 185 90%
Lutchtman et al. [25] 2016 USA SOF/SIM 12w 148 82% 43 88% 193 78% 62 87% 86 78% 94 79% 42 93%
Pellicelli et al. [24] 2016 Italy SOF/SIM/RBV 12w 270 96% – – 270 96% – – – – – – – –
Roytman et al. [23] 2016 USA SOF/SIM 12w 138 89% 43 93% 95 87% 76 87% 55 92% – – – –
Thornton et al. [22] 2016 USA SOF/SIM 12w 114 89% – – – – – – – – – – – –
Jayasekera et al. [19] 2016 USA SOF/SIM 12w 35 86% 13 92% 22 82% 7 86% 28 86% – – – –
Pillail et al. [20] 2016 USA SOF/SIM ± RBV 12w 113 84% 23 91% 90 82% 57 89% 56 79% – – – –
Barron et al. [21] 2016 USA SOF/SIM ± RBV 12w 35 83% – – – – – – – – – – – –
Backus et al. [18] 2015 USA SOF/SIM 12w 1130 75% 664 81% 462 68% 699 78% 431 71% 632 73% 366 80%
DCV daclastavir, GT genotype, SIM simeprevir, SOF sofosbuvir, SVR sustained virological response, w week
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interferon-free drugs is lower than IFN-based regimens,
we could hypothesize that treatment with DAAs might
be dominant in this country. Considering local costs and
SVR rates reported in international real-life cohorts, the
cost per SVR in Brazil could range from 20 to 30 thou-
sand PPP$. Early viral kinetics might be used to
individualize duration of DAA therapy decreasing costs
by up to 20% [40]. On the other hand, treatment of
patients with advanced fibrosis/compensated cirrhosis
for 12 weeks, as recommended by the BMoH guideline,
might lead to relative high rates of DAA failure or resist-
ance and increased future costs for re-treatment. The
addition of RBV (1250 mg PO daily) to SOF/SIM or
SOF/DCV does not highly increase the cost of treatment
due to local generic production and low price (US$ 706
or PPP$ 1273 per patient per 12 week duration). In
Brazil, the prevalence of GT 1b seems to slightly higher
than 1a (55% vs 45%) [41]. Considering our HCV preva-
lence and costs described in the present study, the finan-
cial burden could be up to PPP$ 21 billion (or US$ 12
billion) to treat all GT1 HCV infected people independ-
ently of fibrosis stage in Brazil. This amount represents
approximately 13% of the general government expenditure
on health in Brazil during 2014 [Health expenditure series.
World Health Organization, available at: http://apps.-
who.int/nha/database/Select/Indicators/en; accessed at
March 2017].
The main limitations of the present study are the lack
of primary data on patient’s follow-up and costs of treat-
ment for non-GT1 patients and new generation of
interferon-free regimens. Presence of adverse events
might lead to increased costs for medical care and low
treatment adherence might result in higher costs and
higher costs per SVR than our estimates, due to non-
response/relapse. However, primary data on DAA-
treatment remain scarce in Brazil because the strategy
from BMoH for universal access to SOF, DCV and SIM
has been recently implemented. We estimated the costs
of an ideal follow-up for standard treatment of GT1, the
most prevalent genotype, HCV patients according to
recent BMoH’s recommendations. We are aware that
treatment with fixed dose one-tablet daily of SOF/ledis-
pavir (400/90 mg) or SOF/velpatasvir (400/100 mg) for
12 weeks has been recommended as first-line therapies
for GT1 patients with or without cirrhosis [42]. These
patients can also be treated with the fixed-dose combin-
ation of ombitasvir (12.5 mg), paritaprevir (75 mg) and
ritonavir (50 mg) in one single tablet and dasabuvir
(250 mg) [PTV/r/OMV +DSV regimen] or the fixed
dose combination of grazoprevir (100 mg) and elbasvir
(50 mg) in a single tablet once-daily [42]. However, these
drug combinations are not currently available in Brazil
for cost estimation. Another major limitation might be
the fact that we evaluated the costs for HCV treatment
in a short-term horizon and without prospective follow-
up to evaluate whether DAAs treatment are cost-saving
compared to PEG-IFN regimens.
The main strengths of this analysis are the PPP-
adjustment for costs, the estimation of “real-price” for
HCV-drugs and those related to monitoring/medical
care accounting for the economic costs of public funds
in medical investments. PPP adjustment is essential to
allow comparison of prices of goods and services across
countries. For high-income countries, PPP adjustment
results in lower prices. In contrast, countries with
weaker purchasing power, such as Brazil, have a signifi-
cant increase in prices with PPP adjustment [43]. In the
present study, the PPP-adjustment led to an increase in
1.8 fold in US$ costs. The cost for each drug were de-
fined as the weighted-mean price of all HCV-drugs
bought by the BMoH in 2015 and registered in web-
based and open-access platform. In addition, we ana-
lysed micro-costs of all procedures recommended pre,
during and post-HCV treatment to allow the estimation
of medical care financial burden beyond drug costs.
Conclusions
In conclusion, therapies with all-oral interferon-free, such
as SOF/DCV and SOF/SIM for 12 weeks, have a high effi-
cacy and need shorter treatment duration leading to lower
costs for monitoring and medical care compared to IFN-
based regimens in Brazil where DAAs had more than 90%
discount over international prices. HCV treatment by
IFN-free regimens will probably be associated with high
financial impact worldwide. However, reduced DAA prices
due to negotiation between health authorities and
pharmaceutical companies can turn HCV treatment into
an accessible strategy to HCV eradication.
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